BiotechTube

Tradipitant + Placebo + Open Label Tradipitant

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Gastroparesis

Conditions

Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis

Trial Timeline

Aug 20, 2019 → Feb 21, 2025

NCT ID
NCT04028492

About Tradipitant + Placebo + Open Label Tradipitant

Tradipitant + Placebo + Open Label Tradipitant is a phase 3 stage product being developed by Vanda Pharmaceuticals for Idiopathic Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT04028492. Target conditions include Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04028492Phase 3Completed

Competing Products

20 competing products in Idiopathic Gastroparesis

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77

Other Products from Vanda Pharmaceuticals

tasimelteon 20 mg capsule + tasimelteon 2 mg I.V.Approved
77
IloperidoneApproved
77
ImsidolimabPhase 3
69
Iloperidone + PlaceboPhase 3
69
Iloperidone + Ziprasidone + PlaceboPhase 3
69